ACA
SGMO

Aptus Capital Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Aptus Capital Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$5.43K – 1182
2023
Q4 		$5.43K Buy
+10,000
New +$4.61K ﹤0.01% 832

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Aptus Capital Advisors's SGMO Position: Q1 2024 in Review

Aptus Capital Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2024, closing a stake of 10,000 shares — an estimated $5.43K sold.

Aptus Capital Advisors first reported a position in SGMO in Q4 2023 and held it in 1 quarter. The position peaked at $5.43K in Q4 2023. 131 funds tracked by Wall St. Rank hold SGMO as of Q1 2024.

  • Aptus Capital Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2024 after selling out during the quarter.
  • Aptus Capital Advisors sold 10,000 SANGAMO THERAPEUTICS INC shares in Q1 2024, an estimated $5.43K.
  • Aptus Capital Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2023 and held it in 1 quarter.
  • Aptus Capital Advisors's SANGAMO THERAPEUTICS INC position peaked at $5.43K in Q4 2023.
  • 131 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2024.

Based on Aptus Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.